You are currently viewing Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates

Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates

This Issue of the Bulletin primarily focuses on psychedelic drug development and business stories, with around 4,000 words of coverage and analysis.

Featured content in this Issue:

  • GH Research’s Lead 5-MeO-DMT Candidate Faces Development Hiccup, Potential Hold-Up
  • Psychae Therapeutics Scores AUD $4.5m to Develop DMT-Based Candidate
  • Cybin Closes $30m Offering
  • Brain & Behavior Research Foundation Awards Grants to 8 ‘Young Investigators’ Exploring Psychedelics
  • atai Buys Out Remainder of DemeRx’s Ibogaine Asset; Announces Novel 5-HT2A Agonist Candidates
  • Compass Pathways Commences UK Portion of Phase 3 Trial, Officially Opens Centre for Mental Health Research and Innovation in London
  • Awakn Plans to Commence Enrollment for Phase 3 Study of Ketamine for Severe Alcohol Use Disorder in Q1 2024

Elsewhere, we spoke to to better understand a headline figure from its travel predictions study, which claims that 14% of travellers are interested in a psychedelic retreat in 2024. We also share clippings and commentary on psychedelics-related news stories from around the world, as well as biotech more broadly.

Companies, organisations and drug candidates mentioned in this Bulletin include: GH Research, GH001, Psychae Therapeutics, Tin Alley Ventures, Reconnect Labs, Filament Health, Psychae Institute, Cybin, Tryp Therapeutics, PharmaDrug, atai Life Sciences, DemeRx, DMX-1002, EntheogeniX, EGX-A, EGX-B, Cyclica, EMP-01, VLS-01, Compass Pathways, COMP369, NHS, Awakn Life Sciences, AWKN-P001, Sunstone Therapies, Kanna Health, Relmada Therapeutics, Nue Life, Beckley Waves, Enthea.

PA+ Header Psychedelic Alpha

This content is for Pα+ Subscribers

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

button

Join Button